S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
S&P 500   5,252.74 (+0.08%)
DOW   39,774.15 (+0.04%)
QQQ   444.20 (-0.14%)
AAPL   171.75 (-0.90%)
MSFT   420.47 (-0.23%)
META   487.49 (-1.29%)
GOOGL   150.91 (+0.03%)
AMZN   180.16 (+0.18%)
TSLA   176.35 (-1.94%)
NVDA   902.94 (+0.05%)
NIO   4.51 (-3.43%)
AMD   180.40 (+0.45%)
BABA   72.47 (+1.23%)
T   17.64 (+0.51%)
F   13.19 (+1.00%)
MU   117.87 (-1.07%)
CGC   8.52 (-10.79%)
GE   175.09 (-2.79%)
DIS   122.50 (+1.26%)
AMC   3.66 (-15.67%)
PFE   27.91 (+0.47%)
PYPL   67.13 (+0.84%)
XOM   116.06 (+0.95%)
NASDAQ:HROW

Harrow Health (HROW) Stock Price, News & Analysis

$13.25
+0.52 (+4.08%)
(As of 02:39 PM ET)
Today's Range
$12.70
$13.30
50-Day Range
$9.30
$12.73
52-Week Range
$7.60
$28.25
Volume
433,523 shs
Average Volume
445,398 shs
Market Capitalization
$468.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.47

Harrow Health MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
147.8% Upside
$32.47 Price Target
Short Interest
Bearish
15.55% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of Harrow Health in the last 14 days
Based on 17 Articles This Week
Insider Trading
Acquiring Shares
$592,600 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.39) to $0.94 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.71 out of 5 stars

Medical Sector

463rd out of 939 stocks

Pharmaceutical Preparations Industry

218th out of 433 stocks

HROW stock logo

About Harrow Health Stock (NASDAQ:HROW)

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

HROW Stock Price History

HROW Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Harrow Health (NASDAQ:HROW) PT Lowered to $26.00
Why Is Harrow (HROW) Stock Up 5% Today?
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Earnings Preview: Harrow Health
Harrow (HROW) Fell on Lowering the Guidance
HROWM Harrow Health, Inc. NT CAL 27
Harrow to Present at Two Investor Conferences in November
Harrow Recent Insider Activity
See More Headlines
Receive HROW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:HROW
Employees
182
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.47
High Stock Price Target
$37.00
Low Stock Price Target
$26.00
Potential Upside/Downside
+155.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-24,410,000.00
Pretax Margin
-18.21%

Debt

Sales & Book Value

Annual Sales
$130.19 million
Book Value
$2.01 per share

Miscellaneous

Free Float
30,554,000
Market Cap
$450.13 million
Optionable
Optionable
Beta
0.45
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Mark L. Baum J.D. (Age 49)
    CEO & Chairman
    Comp: $1.07M
  • Mr. Andrew R. Boll C.F.A. (Age 40)
    C.M.A., CFA, CMA, CFO & Corp. Sec.
    Comp: $716.73k
  • Dr. Robert J. Kammer D.D.S. (Age 73)
    Special Advisor
    Comp: $91.88k
  • Mr. John P. Saharek MBA (Age 62)
    Chief Commercial Officer
    Comp: $621.92k
  • Jamie Webb
    Director of Communications & Investor Relations
  • Dr. Dennis E Saadeh Pharm.D.
    Chief of Formulation Strategy
  • Mr. Andrew Livingston
    Chief Innovation Officer
  • Ms. Kim Barratt
    Chief Talent Officer

HROW Stock Analysis - Frequently Asked Questions

Should I buy or sell Harrow Health stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HROW shares.
View HROW analyst ratings
or view top-rated stocks.

What is Harrow Health's stock price target for 2024?

2 Wall Street analysts have issued 1-year price objectives for Harrow Health's shares. Their HROW share price targets range from $26.00 to $37.00. On average, they predict the company's stock price to reach $32.47 in the next year. This suggests a possible upside of 147.8% from the stock's current price.
View analysts price targets for HROW
or view top-rated stocks among Wall Street analysts.

How have HROW shares performed in 2024?

Harrow Health's stock was trading at $11.20 at the start of the year. Since then, HROW stock has increased by 17.0% and is now trading at $13.10.
View the best growth stocks for 2024 here
.

When is Harrow Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our HROW earnings forecast
.

How were Harrow Health's earnings last quarter?

Harrow Health, Inc. (NASDAQ:HROW) issued its quarterly earnings data on Monday, November, 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.12. The company had revenue of $34.27 million for the quarter, compared to the consensus estimate of $37.58 million. Harrow Health had a negative trailing twelve-month return on equity of 29.48% and a negative net margin of 18.75%. Harrow Health's revenue for the quarter was up 50.1% compared to the same quarter last year. During the same period last year, the business earned ($0.06) EPS.

What ETFs hold Harrow Health's stock?

ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include Jacob Forward ETF (JFWD) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What guidance has Harrow Health issued on next quarter's earnings?

Harrow Health issued an update on its FY 2024 earnings guidance on Friday, March, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $180.0 million-, compared to the consensus revenue estimate of $188.7 million.

What other stocks do shareholders of Harrow Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO).

Who are Harrow Health's major shareholders?

Harrow Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Opaleye Management Inc. (10.88%), Vanguard Group Inc. (5.15%), Vanguard Group Inc. (5.15%), Braidwell LP (4.27%), Ophir Asset Management Pty Ltd (1.56%) and Stifel Financial Corp (1.23%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Martin A Makary, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom.
View institutional ownership trends
.

How do I buy shares of Harrow Health?

Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HROW) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners